ARTELO BIOSCIENCES, INC.
No enriched coverage for $ARTL in the last 7 days.
No SEC Form 4 filings for $ARTL in the last 30 days.
See all $ARTL insider activity →Artelo Biosciences (ARTL) was flagged for falling below Nasdaq's $5M minimum value listing standard (MVLS) and is exploring options to regain compliance, such as capital raises or expense management. The SEC proposed a rule change, with comments due Oct 29, 2026, but final timing and terms remain uncertain.
ARTELO BIOSCIENCES, INC. (ARTL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On July 22, 2026, the Securities and Exchange Commission (the “SEC”) approved The Nasdaq Stock Market LLC’s (“Nasdaq”) new listing compliance rule that requires listed companies to maintain a market value of listed securities (“MVLS”) of at least $5,000,00
Artelo Biosciences (ARTL) shares rose 193.98% after filing a patent for ART27.13, a drug candidate for obesity. Preclinical data showed 20% weight loss as monotherapy and 40% in combination with semaglutide. CEO Gregory Gorgas noted unexpected findings, including increased bone mineral density.
Recent ARTL coverage spans technology, corporate actions and regulation.
Potential delisting risk may pressure the stock unless compliance is achieved.
Potential delisting pressure could weigh on ARTL share price.
Positive preclinical results and IP expansion suggest near‑term upside potential.
The new patent and data could boost investor interest in ARTL as a novel obesity therapy, potentially lifting the stock.
Potential new obesity therapy could create partnership or licensing opportunities, boosting ARTL valuation if data translate to humans.
AlphAI scores every news story that mentions ARTL with an AI model for sentiment and relevance, and aggregates insider trades from ARTELO BIOSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Artelo Biosciences (ARTL) was flagged for falling below Nasdaq's $5M minimum value listing standard (MVLS) and is exploring options to regain compliance, such as capital raises or expense management. The SEC proposed a rule change, with comments due Oct 29, 2026, but final timing and terms remain uncertain.
1 min readARTELO BIOSCIENCES, INC. (ARTL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On July 22, 2026, the Securities and Exchange Commission (the “SEC”) approved The Nasdaq Stock Market LLC’s (“Nasdaq”) new listing compliance rule that requires listed companies to maintain a market value of listed securities (“MVLS”) of at least $5,000,00
1 min readArtelo Biosciences (ARTL) shares rose 193.98% after filing a patent for ART27.13, a drug candidate for obesity. Preclinical data showed 20% weight loss as monotherapy and 40% in combination with semaglutide. CEO Gregory Gorgas noted unexpected findings, including increased bone mineral density.
2 min readArtelo Biosciences (ARTL) filed a provisional patent for ART27.13, showing 20% weight loss as monotherapy and 40% with semaglutide in obese mice. The study also found improved glucose tolerance and bone density. The company aims to expand ART27.13's use in obesity, a market projected to reach $200B by 2030.
2 min readArtelo Biosciences (ARTL) reported that its drug ART27.13 achieved 20% weight loss in obese mice, matching semaglutide's results. Combined with semaglutide, weight loss doubled to 40%. ART27.13 showed no effect in lean mice, suggesting potential as an obesity treatment. The company plans to explore partnerships based on these findings.
2 min readArtelo Biosciences (ARTL) announced a 1-for-9 reverse stock split, effective August 31, 2026. The split aims to increase the stock's price and improve marketability. Post-split, there will be approximately 547,774 shares outstanding. Shareholder ownership percentages remain unchanged.
1 min readArtelo Biosciences (ARTL) said it enrolled the first patient in its Phase 2 DREAM trial of ART27.13, an oral once-daily cannabinoid-receptor agonist for glaucoma or ocular hypertension. The company expects interim results later this year. ART27.13 was originally developed by AstraZeneca and is also in a Phase 2 CAReS trial. ARTL last traded at $0.72.
2 min readARTELO BIOSCIENCES, INC. (ARTL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. artl_8k.htm 0001621221 false 0001621221 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 D
2 min readArtelo Biosciences (ARTL) reported positive nonclinical results for ART27.13 in a paclitaxel-induced peripheral neuropathy model. Repeated dosing reduced pain-related behaviors in male and female animals. ART27.13 is in Phase 2 for cancer-related anorexia cachexia syndrome, where interim CAReS data showed weight and activity improvements and safety at up to 1300 µg/day. ARTL shares trade around $1.04.
3 min readArtelo Biosciences (ARTL) reported encouraging nonclinical data for ART27.13 in neuropathic pain models tied to cancer supportive care. In paclitaxel-induced peripheral neuropathy animals, repeated dosing reduced neuropathic pain-related behaviors in both sexes. The stock was $1.032 on Nasdaq, down 4.41%.
2 min read
